Currently, a phase II trial is ongoing for evaluating a similar diphtheria toxin-IL-2 fused protein with high bioavailability in patients with refractory/relapsed CTCL and peripheral T cell lymphomas (44). This evidence concerns the gene IL2 and primary cutaneous T-cell non-Hodgkin lymphoma.